Critical attributes of transdermal drug delivery system (TDDS) – a generic product development review

References

• Paudel KS, Milewski M, Swadley CL, et al. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv 2010;1:109–31
   PubMedGoogle Scholar
• Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004;9:697–703
   PubMed Web of Science ®Google Scholar
• Wokovich AM, Prodduturi S, Doub WH, et al. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm 2006;64:1–8
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Draft Guidance on Rivastigmine. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201278.pdf [last accessed 2 Sep 2012]
   Google Scholar
• US Food and Drug Administration. Draft Guidance on Fentanyl. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM162427.pdf [last accessed 5 Sep 2012]
   Google Scholar
• US Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for Industry Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. December 1999. Available from: http://www.fda.gov/ohrms/dockets/98fr/990236Gd.pdf [last accessed 15 Sep 2012]
   Google Scholar
• US Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for Industry Residual Drug in Transdermal and Related Drug Delivery Systems. August 2011. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/UCM220796.pdf [last accessed 15 Sep 2012]
   Google Scholar
• The European Agency for the Evaluation of Medicinal Products. Note for guidance on modified release oral and transdermal dosage forms: section ii (pharmacokinetic and clinical evaluation) July 1999. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003126.pdf [last accessed 16 Sep 2012]
   Google Scholar
• USP Stimuli Article. Topical and transdermal drug products. Pharmacopeial Forum 2009;35:750–64
   Google Scholar
• Addicks WJ, Flynn GL, Weiner N. Validation of a flow-through diffusion cell for use in transdermal research. Pharm Res 1987;4:337–41
   PubMed Web of Science ®Google Scholar
• Akomeah FK, Martin GP, Brown MB. Variability in human skin permeability in vitro: comparing penetrants with different physicochemical properties. J Pharm Sci 2007;96:824–34
   PubMed Web of Science ®Google Scholar
• Ng S, Rouse J, Sanderson F, Eccleston G. The relevance of polymeric synthetic membranes in topical formulation assessment and drug diffusion study. Arch Pharm Res 2012;34:579–93
   Web of Science ®Google Scholar
• Pabla D, Zia H. A comparative permeation/release study of different testosterone gel formulations. Drug Deliv 2007;14:389–96
   PubMed Web of Science ®Google Scholar
• Franz TJ, Lehman PA, Raney SG. Evaluation of full thickness vs. dermatomed skin on testosterone percutaneous absorption using the in vitro cadaver skin percutaneous absorption model. Available from: http://www.aapsj.org/abstracts/AM_2008/AAPS2008-003071.PDF [last accessed 14 Dec 2012]
   Google Scholar
• Thakker KD, Chern WH. Development and validation of in vitro release tests for semisolid dosage forms – case study. Disso Tech 2003;10:10–15
   Google Scholar
• Venter JP, Muller DG, du Plessis J, Goosen C. A comparative study of an in situ adapted diffusion cell and an in vitro Franz diffusion cell method for transdermal absorption of doxylamine. Eur J Pharm Sci 2001;13:169–77
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for industry nonsterile semisolid dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro release testing and in vivo bioequivalence documentation. May 1997. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM070930.pdf [last accessed 15 Oct 2012]
   Google Scholar
• Fauth C, Wiedersberg S, Neubert RH, Dittgen M. Adhesive backing foil interactions affecting the elasticity, adhesion strength of laminates, and how to interpret these properties of branded transdermal patches. Drug Dev Ind Pharm 2002;28:1251–9
   PubMed Web of Science ®Google Scholar
• Spencer TS, Smith SE, Conjeevaram S. Adhesive interactions between polymers and skin in transdermal delivery systems. Poly Mater Sci Eng 1990;63:337–9
   Google Scholar
• Treffel P, Muret P, Muret-D'Aniello P, et al. Effect of occlusion on in vitro percutaneous absorption of two compounds with different physicochemical properties. Skin Pharmacol 1992;5:108–13
   PubMedGoogle Scholar
• Casiraghi A, Minghetti P, Cilurzo F, et al. Occlusive properties of monolayer patches: in vitro and in vivo evaluation. Pharm Res 2002;19:423–6
   PubMed Web of Science ®Google Scholar
• Minghetti P, Cilurzo F, Liberti V, Montanari L. Dermal therapeutic systems permeable to water vapour. Int J Pharm 1997;158:165–72
   Web of Science ®Google Scholar
• Kulkarni PV, Keshavayya J. Preparation and evaluation of polyvinyl alcohol transdermal membranes of salbutamol sulphate. Int J Curr Pharm Res 2010;2:13–16
   Google Scholar
• Padula C, Colombo G, Nicoli S, et al. Bioadhesive film for the transdermal delivery of lidocaine: in vitro and in vivo behavior. J Control Release 2003;88:277–85
   PubMed Web of Science ®Google Scholar
• Schulz M, Fussnegger B, Bodmeier R. Drug release and adhesive properties of crospovidone-containing matrix patches based on polyisobutene and acrylic adhesives. Eur J Pharm Sci 2010;41:675–84
   PubMed Web of Science ®Google Scholar
• Imani M, Lahooti-Fard F, Taghizadeh SM, Takrousta M. Effect of adhesive layer thickness and drug loading on estradiol crystallization in a transdermal drug delivery system. AAPS Pharm SciTech 2010;11:1268–75
   PubMed Web of Science ®Google Scholar
• Latsch S, Selzer T, Fink L, Kreuter J. Crystallisation of estradiol containing determined by isothermal microcalorimetry, X-ray diffraction, and optical microscopy. Eur J Pharm Biopharm 2003;56:43–52
   PubMed Web of Science ®Google Scholar